VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Checkout @Money _eh

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Sep 14, 2022 3:55pm

83 Views

Post# 34962696

RE:Checkout @Money _eh

theNorm wrote:
on CEO.CA eom

"On August 26, the company announced a sponsorship for the 70th European society of cardiology congress. According to the congress reports, 40,000 participants from 170 countries will hear 5,000 medical presentations during the event, bringing Ventripoint another opportunity to inform the cardiology community how innovative its VMS+ products are.

It comes after echocardiologists in Latin America expressed a strong interest in Ventripoint’s products, according to news shared on August 10. According to the DIC-SBC Conference Chairperson, Dr. Marly Uellendahl, “VMS+3.0 is an innovative technology that generates three-dimensional data from two-dimensional echocardiogram data and will have a major impact on clinical practice for sure, especially in evaluating the right ventricle.” The company has engaged a representative in Brazil. He has initiated discussions with KOLs, distributors, and regulatory consultants to establish a market entry plan and asses the demand for the VMS+ products in this rich region. The regulatory process in Brazil has recently been changed, and it is estimated it will take 6 to 12 months to complete depending on the classification of the VMS+.